Jasper Therapeutics discloses $132 million private securities offering in SEC filing
A Form D filed August 4, 2026 shows Jasper Therapeutics sold $131,999,611 in equity securities to 40 investors under a Rule 506(b) exemption.
Jasper Therapeutics, Inc., based in Redwood City, California, filed a Form D notice with the Securities and Exchange Commission dated August 4, 2026, disclosing an exempt securities offering. The total offering amount and the total amount sold were both listed as $131,999,611, with $0 remaining to be sold.1
The filing lists the date of first sale as July 21, 2026, and marks the notice as a new filing rather than an amendment.1 The securities offered were classified as equity.1 The company claimed a Rule 506(b) exemption under federal securities law.1
The filing states that 40 investors have already invested in the offering.1 The minimum investment accepted from any outside investor was listed as $0.1 No sales commissions or finders' fees were reported in connection with the offering.1 The company indicated the offering was not made in connection with a business combination transaction such as a merger or acquisition.1
The filing categorizes Jasper Therapeutics under the biotechnology segment of the health care industry group.1 The company selected "decline to disclose" for its revenue range and aggregate net asset value range.1
Related persons named in the filing include Herb Cross and Jeet Mahal as executive officers, with Mahal also serving as a director, along with directors Patrick Crutcher, Thomas Wiggans, Judith Shizuru, Svetlana Lucas, Kurt von Emster, and Matthew E. Ros, plus executive officers Wenru Song and Gregory F. Keenan.1
The notice was signed by Herb Cross, identified as Chief Financial Officer, on August 4, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.